Dr Lal PathLabs, Metropolis: Here's how healthcare stocks look on charts

Thyrocare Technologies has the strong support of 50-DMA, currently placed at Rs 988 levels.

Coronavirus, covid, tests
After scaling a new all-time high, the sentiment is bullish for Metropolis Healthcare.
Avdhut Bagkar Mumbai
3 min read Last Updated : Nov 24 2020 | 11:51 AM IST
Shares of diagnostic and healthcare services firms such as Metropolis Healthcare, Dr Lal PathLabs, and Thyrocare Technologies were trading in the positive territory on Tuesday, a day after the Maharashtra government imposed restrictions on all air and rail passengers arriving from Delhi, Gujarat, Rajasthan, and Goa. Passengers travelling from these states — which have seen a significant surge in cases — will have to obtain a negative RT-PCR test report before starting. READ MORE

Among individual stocks, Dr Dr Lal PathLabs rallied as much as 3.57 per cent to Rs 2,375.95 on the BSE while Metropolis Healthcare hit an all-time high of Rs 2,291.60. Thyrocare Technologies, on the other hand, gained over 6 per cent to Rs 1,156.55. In comparison, the benchmark S&P BSE Sensex traded around 0.6 per cent higher. 

So, what lies ahead for these stocks? Take a look at what charts suggest. 

Dr. Lal Path Labs Ltd (LALPATHLAB): In the recent healthy correction, the counter witnessed strong buying and accumulation around Rs 2,100 levels, which is its 50-day moving average (DMA). The weekly chart suggests a closing basis support of Rs 2,050 and an upside bias towards the direction of Rs 2,500 to Rs 2,650 levels. The immediate support comes in at Rs 2,250 and Rs 2,180 level, as per the daily chart. On the higher side, an overwhelming close above Rs 2,350 may see a strong increase in volumes.  CLICK HERE FOR THE CHART
 
Metropolis Healthcare Ltd (METROPOLIS): After scaling a new all-time high of Rs 2,294, the sentiment is bullish for this counter. It has successfully conquered the firm selling pressure range of Rs 2,110 to Rs 2,040. This breakout is indicating a rally towards Rs 2,500 levels. And till the counter defends Rs 2,100 levels on a closing basis, the medium-term outlook may see higher levels of Rs 2,900, as per the daily chart. The Relative Strength Index (RSI) has entered the overbought condition, yet the stock price is not witnessing any major sell-off. CLICK HERE FOR THE CHART
 
Thyrocare Technologies Ltd (THYROCARE): This counter has a strong support of 50-DMA, currently placed at Rs 988 levels. In the last 10 sessions, whenever it dipped near the moving average, it managed to gain buying momentum. This clearly indicates that till the moving average is defended successfully, the upside bias may see Rs 1,250 to Rs 1,320 levels in the coming sessions. CLICK HERE FOR THE CHART  

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Buzzing stocksMaharashtraMarketsCoronavirus TestsDiagnostics

Next Story